< Back to all Breaking News
AIM
6/21/2021 09:06am
AIM ImmunoTech completes all treatments in Phase 1 study of ampligen 
Don't miss out!
We read the Wall Street research, SEC filings and press releases so you don't have to.
Sign up for our 14-day free trial to read this story.
